Marshall Wace, LLP Alaunos Therapeutics, Inc. Transaction History

Marshall Wace, LLP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.5 - $261.0 $754,714 - $394 Million	-1,509,429 Reduced 76.97%	451,698 $293,000
Q3 2022 Nov 14, 2022	BUY	$1.04 - $322.5 $1.39 Million - $430 Million	1,334,596 Added 213.01%	1,961,127 $3.37 Million
Q2 2022 Aug 15, 2022	BUY	$0.41 - $1.24 $256,877 - $776,898	626,531 New	626,531 $777,000
Q1 2022 May 16, 2022	SELL	$0.62 - $1.17 $81,034 - $152,919	-130,700 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.89 $423,103 - $733,637	-388,168 Reduced 74.81%	130,700 $142,000
Q3 2021 Nov 15, 2021	BUY	$1.44 - $2.73 $747,169 - $1.42 Million	518,868 New	518,868 $944,000
Q1 2021 May 17, 2021	SELL	$2.82 - $5.6 $137,511 - $273,072	-48,763 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.09 - $3.09 $8,606 - $12,724	-4,118 Reduced 7.79%	48,763 $123,000
Q3 2020 Nov 16, 2020	SELL	$2.39 - $3.43 $122,975 - $176,487	-51,454 Reduced 49.32%	52,881 $133,000
Q2 2020 Aug 13, 2020	BUY	$2.2 - $3.71 $229,537 - $387,082	104,335 New	104,335 $342,000
Q2 2019 Aug 14, 2019	SELL	$3.98 - $6.2 $293,007 - $456,444	-73,620 Closed	0 $0
Q1 2019 May 14, 2019	SELL	$2.0 - $4.4 $620,792 - $1.37 Million	-310,396 Reduced 80.83%	73,620 $283,000
Q4 2018 Feb 14, 2019	BUY	$1.61 - $3.62 $560,481 - $1.26 Million	348,125 Added 969.95%	384,016 $719,000
Q3 2018 Nov 14, 2018	BUY	$2.26 - $3.27 $81,113 - $117,363	35,891 New	35,891 $115,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $424M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.